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Resumo 
 
O carcinoma de células renais (CCR) é o cancro sólido mais comum do rim no 
adulto, sendo o subtipo mais agressivo o carcinoma de células renais de células claras 
(CCRcc), existindo atualmente várias opções terapêuticas. Contudo, o CCR metastático 
permanece incurável, principalmente devido à aquisição de resistências ao tratamento. 
Além disso, aproximadamente 30% dos doentes já apresentam doença metastática no 
momento do diagnóstico, e 20 a 40% dos doentes com CCR localizado irão apresentar 
progressão da doença. 
Uma das vias de sinalização envolvida na fisiopatologia do CCRcc é a via de 
von Hippel-Lindau (VHL). No entanto, a desregulação da via PI3K/AKT/mTOR 
também está envolvida na oncogénese deste cancro, sendo uma via central na regulação 
do metabolismo, proliferação e sobrevivência celular. Uma das abordagens terapêuticas 
usadas nos doentes de pior prognóstico são os inibidores do mTOR. Estas moléculas 
formam um complexo com a proteína de ligação FK e inibem a ligação do mTOR ao 
complexo 1 (mTORC1), inibindo assim os seus efeitos a jusante. No entanto, o outro 
complexo, mTORC2, não é inibido. Assim, um possível mecanismo de resistência a 
esta terapia poderá ser consequência da ativação compensatória da via PI3K/AKT, 
provavelmente devido à sobre-regulação do mTORC2. 
Atualmente admite-se que os microRNAs (miRNAs) estão também envolvidos 
na aquisição de resistências a terapias dirigidas em vários tipos de cancro. Os miRNAs 
são uma família de pequenos RNAs não codificantes responsáveis pela regulação génica 
a um nível pós-transcripcional e a sua desregulação está descrita em diversos tipos de 
cancro, incluindo o CCRcc. Assim, o estudo dos perfis de expressão de miRNAs 
durante o desenvolvimento de CCRcc e a sua influência na aquisição de fenótipos de 
resistência, será um potencial alvo de estudo. 
O principal objetivo deste estudo foi clarificar a influência do miRNA-101 no 
desenvolvimento de resistência aos inibidores mTOR em CCRcc e o seu potencial como 
biomarcador molecular.  
Para o desenvolvimento deste estudo foram usadas quatro linhas celulares como 
modelo in vitro: uma linha celular renal epitelial proximal tubular normal (HKC-8), 
duas linhas celulares de adenocarcinoma renal (786-O e FG-2) e uma linha celular renal 
tumoral resistente a everolimus (estabelecida durante o desenvolvimento deste projeto). 
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A quantificação dos níveis de miRNA-101 foi avaliada nas células (intracelular) e no 
respetivo meio de cultura (extracelular), a par da adicional quantificação relativa da 
expressão de mRNA do mTOR, Rictor, Raptor e HIF-2a. 
De acordo com os nossos resultados, foi observado uma diminuição significativa 
dos níveis intracelulares de miRNA-101 nas duas linhas celulares tumorais, quando 
comparada com a HKC-8 (786-O vs HKC-8: P=0.030 e FG-2 vs HKC-8: P=0.003). 
Para além disso, este miRNA apresentou níveis extracelulares significativamente 
aumentados na linha celular FG-2 (P<0.001) e tendencialmente superior na 786-O 
(P=0.052). Adicionalmente, a expressão dos níveis intracelulares do miRNA-101 foi 
tendencialmente menor na linha celular resistente (786-OR) quando comparada com a 
linha celular 786-O (P=0.064). Foi também observado um aumento da expressão de 
miRNA-101 no meio das 786-OR (786-OR vs 786-O: P=0.004). Assim, ao longo da 
aquisição de resistência ao everolimus, as células começam a excretar maior quantidade 
de miRNA-101. 
Em relação aos níveis de Rictor, observámos um aumento significativo na linha 
786-O (P<0.001) quando comparado com a linha HKC-8. No entanto, observámos uma 
diminuição deste mRNA na linha FG-2 (FG-2 vs HKC-8: P=0.031). A sua expressão 
nas 786-OR é significativamente menor quando comparada com as 786-O (P=0.003). 
Relativamente ao Raptor, a expressão está aumentada em ambas as linhas tumorais 
comparativamente com as HKC-8 (786-O vs HKC-8: P<0.001 e FG-2 vs HKC8: 
P=0.08) e significativamente menor nas 786-OR quando comparadas com as 786-O 
(P<0.001). Em relação ao HIF-2a, a sua expressão é significativamente maior em 
ambas as linhas tumorais comparativamente com as HKC-8 (786-O vs HKC-8: P<0.001 
e FG-2 vs HKC-8: P=0.016) e nas 786-OR comparativamente com as 786-O (P=0.003). 
De acordo com os nossos resultados, tanto o mTORC1 como o mTORC2 
aparentam ser influenciados pelo everolimus, mas não completamente inibidos, o que 
poderá estar associado com o desenvolvimento de resistência. Outro principal fator 
neste fenótipo de resistência poderá ser a elevação dos níveis de HIF-2a. 
Em conclusão, o miRNA-101 é um potencial biomarcador preditivo de 
resistência aos inibidores mTOR, uma vez que é excretado pelas células resistentes a 
estes. No futuro, a análise dos níveis circulantes de miRNA-101 em amostras 
sanguíneas de doentes com CCRcc poderá permitir uma melhor monitorização da 
resposta a este tipo de tratamento.  
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Abstract 
 
Renal cell carcinoma (RCC) is the most common solid cancer of the adult 
kidney, being the most aggressive subtype the clear cell RCC (ccRCC) and there are a 
wide variety of treatments. The metastatic disease remains incurable mainly in 
consequence of the acquisition of treatment resistances. Moreover, approximately 30% 
of patients’ present with already metastasized disease at the time of diagnosis, and 20-
40% of the patients with localized RCC will present disease progression. 
One of the signaling pathways involved in the pathophysiology of ccRCC is the 
von Hippel-Lindau (VHL) pathway, however the deregulation of the PI3K/AKT/mTOR 
pathway is also involved in the oncogenic mechanisms observed in ccRCC, and it 
serves as a central regulator of cell metabolism, proliferation and survival. One 
therapeutic approach used in ccRCC patients, that present a worst prognosis, are the 
mTOR inhibitors. These molecules form a complex with the FK binding protein and 
inhibit mTOR from binding complex 1 (mTORC1), thereby inhibiting its downstream 
effects. However, the other mTOR complex - mTORC2 - is not inhibited by these 
targeted therapies. Thus, the resistance mechanism can be mainly through compensatory 
activation of PI3K/AKT pathway probably via upregulation of mTORC2.  
Additionally, microRNAs (miRNAs) also seem to be involved in targeted 
therapy resistance acquisition in several cancers. MiRNAs are a family of small non-
coding RNAs, that are responsible for the regulation of gene expression at a post-
transcriptional level, and have been reported as deregulated in several cancers including 
ccRCC. As so, it would be important to study the expression patterns of these molecules 
in ccRCC and evaluate their influence in resistance acquisition phenotypes, specially 
their influence in mTOR inhibitors patients’ response. 
The main aim of this study was to clarify the influence of miRNA-101 in ccRCC 
resistance development to mTOR inhibitors and its potential as molecular biomarker. 
To perform this study, four cell lines were used as in vitro model: one normal renal 
proximal epithelial tubular cell line (HKC-8), two renal adenocarcinoma cell lines (786-
O and FG-2) and an everolimus-resistant tumoral renal cell line (786-OR), the last one 
established during the development of this project. The quantification of miRNA-101 
expression in the cells (intracellular) and in the respective medium (extracellular) was 
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assessed. This was accompanied by the relative quantification of mTOR, Rictor, Raptor 
and HIF-2a mRNA expression. 
 We observed a significant decrease of miRNA-101intracellular levels, in both 
tumoral cell lines, 786-O and FG-2, when compared with HKC-8 (786-O vs HKC-8: 
P=0.030 and FG-2 vs HKC-8: P=0.003). Moreover, this miRNA presented higher 
extracellular levels in FG-2 (P<0.001) and presented a tendency to be higher in 786-O 
(P=0.052). Additionally, the expression of miRNA-101 intracellular levels presented a 
tendency to be lower in the resistant cell line (786-OR) when compared with 786-O 
(P=0.064). This was accompanied by an increase of miRNA-101 expression in 786-OR 
medium (786-OR vs 786-O: P=0.004). Thus, along the resistance acquisition to 
everolimus, the cells started to excrete more miRNA-101.  
Regarding Rictor levels, we observed a significant difference between 786-O 
and HKC-8 cell lines with a fold-increase of 3.36 (P<0.001). However, we observed a 
decrease of this mRNA in FG-2 cell line (FG-2 vs HKC-8: P=0.031). Additionally, the 
Rictor expression in 786-OR decreased when compared with 786-O (P=0.003). 
Regarding Raptor levels, we found an increase of this mRNA expression in both 
tumoral cell lines, 786-O and FG-2, when compared with HKC-8 (786-O vs HKC-8: 
P<0.001 and FG-2 vs HKC8: P=0.08). We also observed a significant decrease of this 
mRNA in 786-OR when compared with 786-O (P<0.001). In relation to HIF-2a 
expression levels, we found a significant increase of this mRNA in both tumoral cell 
lines, 786-O and FG-2, when compared with HKC-8 (786-O vs HKC-8: P<0.001 and 
FG-2 vs HKC-8: P=0.016). This was accompanied by an increase of HIF-2a expression 
in 786-OR when compared with 786-O (P=0.003).  
 According to our results both mTOR complexes (mTORC1 and mTORC2) seem 
to be affected by everolimus treatment, but not completely inhibited, which may be 
associated with the development of resistance. Another major contributor to the 
acquisition of the resistant phenotype seems to be HIF-2a elevation. 
In conclusion, miRNA-101 is a potential predictive biomarker of resistance to 
mTOR inhibitors since it is excreted by everolimus resistant cells. In the future, the 
circulating levels of miRNA-101 analysis in blood samples may allow an improvement 
in monitorization of everolimus resistance acquisition in ccRCC patients submitted to 
mTOR inhibitors. 
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1. Introduction 
1.1  Cancer: general concepts 
 
Cancer is the second leading cause of death worldwide [1]. According to the 
World Health Organization (WHO), this disease was responsible for 8.8 million deaths 
in 2015 and the number of new cases is expected to rise in about 70% over the next two 
decades [2]. In fact, in the last year’s cancer incidence has been increasing and it is 
expected that this number will exceed the 20 million in 2025. This scenario may be due 
to the population ageing and to the exposure to several risk factors that promote 
carcinogenesis such as: tobacco consumption, alcohol, unhealthy diet and physical 
inactivity [3, 4].  
Cancer is considered a heterogeneous disease that develops through interactions 
between environmental and genetic factors, involving dysregulation of multiple 
pathways responsible for the fundamental cell process, such as death, proliferation, 
differentiation and cell migration [3]. Thus, the cancer-forming process, called 
carcinogenesis, is a multifactorial and multiphasic process, which is associated with 
genetic and epigenetic modifications that promote the development of a malignant 
neoplasia [5]. Carcinogenesis can be divided into three main phases: initiation, 
promotion and progression [6]. In the first phase, it occurs different damages in cells in 
deoxyribonucleic acid (DNA). These damages may have origin in different types of 
carcinogenic factors such as tumor-promoting chemicals, biological and/ or viruses [7]. 
Subsequently, promotion is a reversible process that involves a selective clonal 
expansion of initiated cells leading to the growth and malignant conversion. During this 
phase, additional genomic and epigenomic lesions occur.  Finally, the genetic changes 
that underlie oncogenesis alter several fundamental properties of cells, conferring the 
full cancer phenotype. There are two main classes of genes implicated in the 
development of cancer: oncogenes and tumor-suppressor genes [5]. Proto-oncogenes 
encode growth-promoting signal molecules and their receptors, anti-apoptotic proteins 
and some transcription factors. Conversion, or activation, of a proto-oncogene into an 
oncogene generally involves a gain-of-function mutation. Tumor-suppressor genes 
normally inhibits cell growth, so mutations that inactivate them allow inappropriate cell 
division [8, 9].   
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Cancer cells also acquire other properties that give them an advantage over the 
normal ones, such as higher proliferative capacity, angiogenesis and invasive potential 
[10, 11]. In fact, Hanahan and Weinberg proposed a set of cellular characteristics that 
allow the differentiation of the tumor cells known as the Hallmarks of cancer. Initially, 
six fundamental cellular properties were defined: sustaining proliferative signaling, 
evading to growth suppressors, resisting cell death, enabling replicative immortality, 
angiogenesis induction and invasion and metastasis activation [11]. More recently these 
authors added new Hallmarks such as: the capacity to avoid immune destruction, 
inflammation promotion, metabolism dysregulation and genetic instability which 
promote tumor development (Figure 1) [10].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the advances in the early diagnosis and in the development of new 
treatments, it still difficult to control cancer development. Thus, the constant evolution 
in cancer research is an important need, to understand the tumor progression and the 
nature of tumor cell interactions in their microenvironment, which ultimately lead to the 
development of new anti-neoplasic therapeutic agents and approaches.    
 
 
Figure  1 – The Hallmarks of Cancer (adapted from Hanahan, D. and Weinberg, R. 2011) [10].  
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1.2 Renal Cell Carcinoma 
 
Renal cell carcinoma (RCC) is the most common renal malignancy, representing 
approximately 2% of all cancers, and it is the mostly lethal urological cancer [12]. 
Kidney cancer accounts for approximately 84.000 new cases and 35.000 deaths in 
Europe every year [13]. Actually, there is a 2:1 male predominance, with a peak 
incidence between 60 and 70 years [13]. According to RORENO (Registo Oncológico 
Regional do Norte), in 2010 kidney cancer became part of the 10 most incidence 
cancers in the North of Portugal, which shows the incidence increase in the last years 
[14]. RORENO also estimates that there will be 451 new cases of kidney cancer by 
2020 opposing to the 286 cases stated in 2008 [15]. Moreover, RCC incidence and 
mortality rates presents a geographic variation. The highest incidence rates are observed 
in the Northern America, Western Europe and Australia, whereas the lowest are 
observed in India, China and Africa. In relation to mortality rates they are higher in the 
Central and Eastern countries of Europe and they are lower in Middle and Western 
Africa (Figure 2) [16]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2 – Distribution of incidence and mortality rates of kidney cancer (Globocan 2012, IARC). 
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Nowadays, the majority of RCC diagnoses can result from incidental findings 
due to the anatomical location of the kidney. These “incidentalomas” are a 
consequence of the use of radiological techniques, such as ultrasound and computer 
tomography performed for other clinical purposes [13]. Additionally, the anatomic 
location of the kidney is also responsible for the fact that renal masses remain 
asymptomatic and non-palpable until the late stages of the disease. Patients with worse 
prognosis are diagnosed after presenting flank pain, gross haematuria and a palpable 
abdominal mass [17].  
RCC is a heterogeneous cancer which is divided into various subtypes, each 
derived from a different part of nephron with different genetic and molecular 
alterations, histological features, clinical phenotypes and prognosis [18]. The major 
subtypes are the clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe 
RCC (chRCC) [19, 20]. The most common subtype of RCC is ccRCC, accounting for 
approximately 80% of all cases, and it is histologically characterized by high cell lipid 
content and richly vascularized tumor stroma [21]. ccRCC is the most aggressive 
subtype and it is associated with a high risk of metastasis formation [22]. The staging of 
each patient was made according to the AJCC TNM classification system. The TNM 
staging system is based on primary tumors (T), the involvement of lymph nodes (N) and 
whether the tumour has metastasized (M) [13]. The figure 3 represents the stages of 
RCC and management options of each stage.  
 
 
Figure  3 – The stages of RCC and management options (adapted from Hsieh, J. J., et al. 2017)  [13]. 
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The classification system most widely accepted for histologic grading of RCC is 
the Fuhrman nuclear grade. The Fuhrman grading system is based on assessment of the 
uniformity of nuclear size, nuclear shape and nucleolar prominence. Fuhrman nuclear 
grades 1-2 are associated with tumors in initial stages of development and better 
prognosis and 3-4 with worst prognosis due to a greater tumor malignancy and 
aggressiveness [23].  
According to the European Association of Urology, the standard treatment of 
RCC is surgical excision by either partial or radical nephrectomy for patients with 
surgically resectable tumors [24]. However, approximately 30% of patients initially 
present with already metastasized disease, and 20-40% of the patients with localized 
RCC will present disease progression [25]. In cases of patients with inoperable or 
metastatic RCC the treatment resides in the use of target therapies related with key 
signaling pathways deregulated in RCC (mTOR and angiogenesis inhibitors) and/or 
immune check-point inhibitors [26, 27].  
One of the signaling pathways involved in the pathophysiology of ccRCC is the 
von Hippel-Lindau (VHL) pathway. In normoxic conditions, the protein encoded by the 
VHL gene serves as recognition site for the regulatory subunits of hypoxia-inducible 
factors (HIF), targeting them with ubiquitin to proteasome degradation (Figure 4A) 
[28]. In consequence of the alterations of VHL gene, due to the loss of the short arm of 
chromosome 3, or its inactivation or mutation, the degradation of HIF stops and leads to 
its accumulation in the cytoplasm and further migration to the nucleus, where it binds to 
hypoxia-related genes, leading to a cell hypoxic response in normoxic conditions also 
known as “pseudo-hypoxia” [28]. HIF is composed of a a subunit (HIF-1a, HIF-2a and 
HIF-3a subunits) and a b subunit (HIF-1b/ARNT). Whereas HIF-1b is constitutively 
present, the HIF-a members are highly unstable [29]. These alterations lead to the 
transcriptional activation of genes involved in pathways responsible for angiogenesis 
and cell growth, such as the transcription of the platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF) (Figure 4B) [29].   
It has also been described that HIF expression is dependent of mTOR 
(Mechanistic target of rapamycin), another molecule involved in ccRCC development 
[30]. The mTOR protein is a highly-conserved serine/threonine kinase that belongs to 
the phosphoinositide 3-Kinase (PI3K) – related kinase family. The mTOR signaling 
pathway integrates both, intracellular and extracellular signals, and serves as a central 
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regulator of cell metabolism, growth, proliferation and survival [31]. mTOR is a 
downstream effector of the PI3K/AKT pathway and it is also activated by genetic 
alterations that reduce the function of the tumor suppressor protein phosphatase and 
tensin homolog (PTEN) or increase the function of the catalytic subunit of PI3K leading 
to abnormal activation of AKT leading to activation of mTORC1 (mTOR complex 1) 
and mTORC2 (mTOR complex 2) (Figure 4C) [32]. Deregulation of these pathways 
contributes to the aggressiveness of RCC, allowing the development of new therapies 
directed to these pathways in the last years.  
 
 
RCC is traditionally characterized as chemo- and radio-resistant because of the 
high vascular nature of these tumors and constitutive hypoxic state, respectively, which 
leads to a poor prognosis reinforcing the need of new treatment approaches [33]. 
Actually, there are two major types of target agents used in advanced RCC 
treatment according to the key pathways deregulated: angiogenesis inhibitors that 
targeted the VEGF ligand (Bevacizumab) or VEGF receptors (VEGFR) (such as the 
tyrosine kinase inhibitors (TKIs): Axitinib, Sunitinib, Pazopanib and Sorafenib) and 
inhibitors of the mTOR signaling pathway (Everolimus and Temsirolimus) (Figure 5) 
[19, 34].  
 
Figure  4 - Signaling pathways involved in renal cell carcinoma pathophysiology. (A) pVHL pathway under 
normoxic conditions. (B) pVHL pathway under hypoxic conditions. (C) PI3K pathway activation leading to HIF-a 
expression (adapted from Dias, F., et al. 2013) [58]. 
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In terms of therapy response, Ravaud and co-workers divided the patients in 
three groups: there is a subset of patients, approximately 25%, that are resistant to 
therapy when they were initially assessed for response after 2–3 months of therapy; a 
larger group of patients experience tumour regression initially, followed by a short 
period of disease stability and then disease progression after 6–12 months of treatment 
and, ultimately, there is a subset of patients that experience tumour regression during 
the first few months of therapy followed by a longer period of disease stability with no 
new lesions appearing [35]. 
Additionally, cytokine therapies (IL-2 and IFN-a) constitute an alternative to the 
standard metastatic RCC treatment.  Interferon alpha (IFN-a) and/or Interleukin 2 (IL-
2), activate diverse immune effector cells have improved disease control rates and 
clinical outcomes. However, the significant toxicities of cytokines and the fact that they 
present less clinical efficacy when compared with TKIs limits the use of these therapies 
[36, 37]. More recently, a new treatment approach has been developed, which 
modulates the immune system against tumour cells. This treatment targets the 
programmed death 1 (PD-1) receptor which include Nivolumab and Pembrolizumab 
and its ligand (PD-L1), which include Avelumab and Atezolizumab leading to 
inhibition of the PD-1 checkpoint pathway [38]. PD1 negatively regulates T cell 
function and its ligand PDL1 is highly expressed by cancer cells, thus blockade of the 
PD1-PDL1 axis promotes T cell activation and immune killing of the cancer. However, 
Figure  5 – Biological pathways targeted for therapy in RCC (adapted from Rini, B. I. & Atkins, M. B. 2009) [44]. 
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the response to Nivolumab only occurs in 25% of patients and others treated patients’ 
did not experience significant tumour reduction [39].  
In fact, it is important to note that, despite the prognosis improvement of 
metastatic RCC patients and the variety of target therapies available, the treatment 
response is varied and the majority of patients will eventually present disease 
progression [12]. Metastatic disease remains incurable mainly due to the toxicity 
profiles and the development of resistances [40]. Additionally, several questions remain 
unanswered in terms of the alternative sequences treatment and the benefits of using 
multiple agents or even overcoming treatment resistance.  
 
1.2.1 Resistant mechanisms to target therapies  
 
The target agents approved for RCC treatment have increased the progression 
free survival and the overall survival [41]. However, these treatments have specific 
toxicity profiles, which can lead to dose reduction and even discontinuation of the 
treatment [42]. On the other hand, cytokine therapies only present benefit in a small 
subset of patients (generally those with intrinsically favourable disease biology) and are 
associated with substantial toxicity, particularly in the case of IL-2 use [12, 37].  
In general, the resistance to target therapies develops, when a tumor becomes 
independent from the activity of drug targeted pathway [43]. It may happen due to 
several mechanisms (Figure 6). According to Malouf and co-workers the advances in 
RCC therapeutic schemes have led to resistance to first-line treatments, such as 
resistance to TKIs  [30]. The resistance to VEGFR inhibitors is often due to mutation in 
a gene encoding a key receptor tyrosine kinase. However, these mutations would have 
to take place in the tumour endothelium, which is the main target of VEGFR inhibitors 
and it is almost impossible that identical mutation coexists on each individual tumour 
metastasis [44].  
Another potential resistance mechanism is the upregulation of alternative 
proteins and/or pathways that re-establish angiogenesis and growth capacity in an 
independent VEGF manner [44]. For example, alternative angiogenesis can be triggered 
by the upregulation of angiopoietin 2, c-MET (hepatocyte growth factor receptor) or IL-
8 (Interleukin-8) signaling, whereas the proliferation can be promoted through 
upregulation of the PI3K/AKT/mTOR pathway [30].  
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Other resistance mechanism involves the occurrence of an increased drug efflux 
which can results in a decreased intracellular TKIs concentrations [40, 45]. TKIs are 
captured and stored in intracellular compartments instead of reaching cancer cells 
promoting low concentrations in plasma and serum. Inflammation promotion is another 
mechanism of resistance. Bone marrow derived cells modulate expression of a wide 
variety of cytokines, growth factors and enzymes. They are recruited as a result of 
hypoxia occurrence, which in turn is caused by vascular regression mainly due to anti-
angiogenic therapy. This type of cells has the ability to create new blood vessels 
promoting tumor adaptation and resistance to targeted therapies [43].  
Regarding the mTOR inhibitors, they form a complex with the FK binding 
protein (FKBP) and inhibit mTOR from complex 1 (mTORC1). However, the other 
mTOR complex, the mTOR complex 2 (mTORC2) may not be inhibited by these 
targeted therapies [44]. This fact suggests that inhibition of mTORC1 may leads to a 
compensatory activation of PI3K/AKT pathway via upregulation of mTORC2, which 
will activate AKT and HIF-2a, limiting the therapeutic effect of mTOR inhibitors [40].  
 
 
 
 
 
 
The mTOR inhibitors act inside the tumor cell and they are the first line of 
treatment in patients with poor prognosis [37, 46]. Therefore, it is important to study the 
molecular pathology of RCC and PI3K/AKT/mTOR pathway involvement to 
understand these mechanisms of resistance. 
Figure  6 – Mechanisms of resistance to target therapies of RCC (adapted from Rini, B. I. & Atkins, M. B. 2009) [44]. 
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1.3 PI3K/AKT/mTOR pathway  
 
The PI3K (phosphatidylinositol 3-kinase) pathway is a signal transduction 
cascade that is responsible for many physiological functions, including cell cycle, cell 
survival, protein synthesis, metabolism, motility and angiogenesis [32, 47]. The PI3K 
family is divided into four different classes: Class I, Class II, Class III and Class IV. 
Class I are heterodimeric molecules composed by a regulatory subunit: PIK3R1, 
PIK3R2 and PIK3R3 and a catalytic subunit: PIK3CA, PIK3CB and PIK3CD. The class 
IV is composed by ATM (ataxia telangiectasia mutated), DNA-PKcs (DNA-dependent 
protein kinase) and mTOR (mammalian target of rapamycin) [48].   PI3K converts its 
substrate phosphatidylinositol 4,5-biphosphate–PI (4,5) P2 into PI (3,4,5) P3 (or PIP3). 
However, PTEN antagonizes PI3K activity and negatively regulates Protein Kinase B 
signaling. Protein Kinase B, also known as AKT is a serine/threonine-specific protein 
kinase that plays a key role in multiple cellular processes [31].  
AKT can appear in one of three isoforms (AKT1, AKT2, AKT3) [31]. 
Phosphoinositide-dependent kinase 1 (PDK1) is recruited to the membrane and 
phosphorylates AKT at Ser308 and mTORC2 phosphorylates AKT at Ser473 promoting 
full activation of AKT [49]. AKT inhibits through phosphorylation TSC1/TSC2 
(tuberous sclerosis complex). TSC1/2 functions as a GTPase-activating protein (GAP) 
and negatively regulates mTORC1 signaling by converting Rheb (Ras homolog 
enriched in brain) into its inactive form. The active form of Rheb directly interacts with 
mTORC1 to stimulate its activity [50-52].  
mTOR is a downstream effector of the PI3K/AKT pathway and the catalytic 
subunit of the two biochemically distinct complexes, called mTORC1 and mTORC2 
(Figure 7) [53]. mTORC1 has five components: mTOR, which is the catalytic subunit 
of the complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal 
with Sec 13 protein 8 (mLST8, also known GbL); proline-rich AKT substrate 40 kDa 
(PRAS40) and DEP-domain-containing mTOR-interacting protein (Deptor). mTORC2 
comprises six different proteins, some of them common to mTORC1: mTOR; 
rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-activated 
protein kinase interacting protein (mSIN1), protein observed with Rictor-1 (Protor-1); 
mLST8 and Deptor [32, 54]. It is important to note that each complex has its own 
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protein composition, which reflects their differences in terms of upstream signal 
integration, substrate regulation and biological process control.  
 
 
 
 
 
 
 
 
 
 
 
 
mTORC1 is regulated by nutrients, growth factors, cellular energy and stress 
pathways while mTORC2 is primarily regulated by growth factors [32, 50]. 
Additionally, mTORC1 and mTORC2 are both positively regulated by interferons 
(IFNs). The mTOR complexes have distinct functions: mTORC1 positively regulates 
cell growth and proliferation by promoting many anabolic processes, including 
biosynthesis of proteins, lipids and organelles and by limiting catabolic processes such 
as autophagy while mTORC2 plays key roles in various biological processes, including 
cell survival, metabolism, proliferation and cytoskeleton organization [31]. mTOR 
signaling is often deregulated in ccRCC, which can lead to an up regulation of HIF and 
a worse patients’ prognosis [31, 55]. Additionally, it is important to identify new targets 
and consequently, the development of new forms of treatment. Several studies described 
the involvement of microRNAs (miRNAs) dysregulation in the pathogenesis and 
progression of ccRCC [56]. These small molecules can be considered as potential 
diagnostic and prognostic biomarkers, allowing disease monitorization, as well as 
promising new therapeutic agents [40]. 
 
Figure  7 –  Schematic representation of the PI3K/AKT/mTOR pathway and its relation with HIF. It is interesting to note 
that the different HIF subunits are related to different mTOR complexes: HIf-1a is regulated by mTORC1 while HIF-2a is 
regulated by mTORC2 (adapted from Nogueira I., et al. 2018) [69]. 
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1.4 MicroRNAs 
 
MiRNAs are a class of short non-coding RNA (ncRNA) molecules 
(approximately 22 nucleotides of length) that regulate gene expression at the post-
transcriptional level, by binding to the complementary region of corresponding mRNAs 
targets, leading to the inhibition or degradation of mRNAs [57, 58].  
The primary transcripts of miRNAs are produced in the nucleus. Primary 
miRNAs (pri-miRNA) are transcribed by RNA polymerase II and they are processing 
by Drosha and its cofactor DGCR8, creating a pre-miRNA [59, 60] . The pre-miRNAs 
are carried out to the cytoplasm by the nuclear export protein (XPO5), where it is 
cleaved by Dicer to generate the mature double-stranded miRNA [61]. The mature 
miRNAs are incorporated into the RNA-induced silencing complex (RISC) which will 
guide them to the complementary region of their targets and this process results in the 
inhibition of mRNA (messenger ribonucleic acid) translation, or promotes its 
degradation and leads to post-transcriptional gene silencing (Figure 8) [62-64] . 
Recent publications suggest that miRNAs have an important role in cancer 
development, influencing all cancer hallmarks [10]. miRNA expression is dynamic since 
a miRNA can regulate more than one mRNA while different miRNAs can interact with 
the same mRNA [65]. Several studies have shown that miRNAs are expressed or 
inhibited in different types of cancer, suggesting that miRNAs work as onco-miRNAs 
and downregulating tumor suppressor genes, being overexpressed in cancer cells or 
tumor suppressor miRNA, downregulating oncogenes, being under-expressed in cancer 
[57, 66, 67]  
 
 
 
 
 
 
 
 
 
 Figure  8 – MicroRNAs regulation mechanisms (adapted from Teixeira, A.L., et al. 2014) [57]. 
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The circulating levels of specific miRNAs are promising noninvasive blood-
based biomarkers with a high potential for the early RCC diagnosis and monitorization 
of therapy response since they may be predictive of resistance therapies. For example, 
according to a previous publication from our group, the increased plasma levels of 
miRNA-221 has a key role in cellular microenvironment, modulating important cellular 
processes involved in carcinogenesis and cancer progression. This study reports that 
patients with higher plasma miRNA-221 levels had a significantly lower survival rate 
and a high risk of death by RCC [68].  
Since miRNAs may be associated with pathogenesis of RCC and may be 
predictive of resistance therapies it would be important to study the role of miRNAs in 
acquiring resistance to mTOR inhibitors.  
 
1.4.1 MicroRNAs as regulators of PI3K/AKT/mTOR pathway 
 
The PI3K/AKT/mTOR pathway, is perhaps the most commonly activated 
signaling pathway in human cancer. Bibliographic review was done in order to 
understand which miRNAs are associated with this pathway (Attachment 1) [69]. 
Nowadays, it is known that miRNAs have an important role in regulation of mTOR 
signaling in most cancer types (Figure 9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  9 – Schematic representation of the microRNAs that are involved in the regulation of 
PI3K/AKT/mTOR pathway in cancer (adapted from Nogueira I., et al. 2018) [69]. 
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PI3K/AKT/mTOR pathway is induced as a consequence of one the first 
molecular events associated with RCC, the HIF deregulation, and miRNAs have been 
clearly demonstrated to have relationships with mTOR signaling pathway in RCC [70].  
Zheng and co-workers showed that miRNA-101 level was significantly lower in 
human RCC tissues and cell lines and inhibits indirectly the mTOR pathway by 
targeting DNA-PKcs, a member of PI3K, and that regulates mTORC2 activation [71].  
Because mTOR is a validated therapeutic target for RCC, and the clinical 
practice is facing some issues due to de development of resistance to anti-mTOR 
therapies, circulating miRNAs, may be used to predict the resistance to these therapies 
since may be detected by a liquid biopsy  [67, 70]. Therefore, it would be interesting to 
study the miRNAs deregulated in RCC that can be used as prognostic biomarkers. 
Additionally, they can be used as predictive of resistance allowing changings in the 
therapeutic approach, with a significant impact in patients’ overall survival. 
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2. Objectives 
 
2.1 Main Objective 
 
MicroRNA-101 and associated levels of mTORC2 and HIF-2a in resistance 
development to mTOR inhibitors in ccRCC.  
 
2.2 Specific Objectives  
 
• In vitro quantification of miRNA-101 levels (intra- and extracellulary) in renal 
cell carcinoma cell lines (FG-2 and 786-O) versus primary renal proximal tubule 
epithelial cell line (HKC-8); 
• In vitro quantification of HIF-2a, Rictor, Raptor and mTOR mRNA in renal cell 
carcinoma cell lines (FG-2 and 786-O) versus primary renal proximal tubule 
epithelial cell line (HKC-8);  
• Establishment of an everolimus-resistant renal cell carcinoma cell line (786-
OR); 
• Evaluate the potential of miRNA-101 as a molecular biomarker of resistance 
acquisition to everolimus; 
• In vitro quantification of HIF-2a, Rictor, Raptor and mTOR mRNA in 786-OR. 
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3. Material and Methods 
3.1 Cell line characterization and cell culture 
 
Three cell lines were used to perform the present study: HKC-8, 786-O and FG-
2 (Figure 10). The HKC-8 cell line is a human-derived normal renal proximal epithelial 
tubular cell line. The 786-O is a renal cell adenocarcinoma cell line derived from a 58 
years old man and FG-2 is derived from a 77 years old man and it is described as a 
metastatic RCC cell line. Both HKC-8 and FG-2 were kindly provided by Professor 
Klaas Kok from Groningem University, Netherlands and the 786-O cell line was kindly 
provided by Professor Cármen Jerónimo from the Epigenetics and Cancer Biology 
Group of CI-IPO-Porto. 
 
 
 
 
 
Initially a cryopreserved vial of each cell line was thawed. Both 786-O and FG-2 
cells were maintained in RPMI 1640 (1X) medium (Gibco®), supplemented with 10% 
of FBS (Fetal Bovine Serum) (Gibco®) and 1% of Pen-Strep (penicillium-stretomycin 
mixture) (Gibco®). HKC-8 cells were maintained in DMEM/F12 medium (Gibco®), 
supplemented with ITS (Insulin-transferrine-selenum) (Sigma-Aldrich®), Pen-Strep 
(Gibco®), EGF (Epidermal Growth Factor) (Sigma-Aldrich®), Hepes buffer (Gibco®) 
and Hydrocortisone (Sigma-Aldrich®). The three cell lines were kept in an incubator 
with the following conditions: 37ºC of temperature, 5% CO2 and humid atmosphere. 
 
 
 
 
Figure 10 – (A) Microscope image of the HKC-8 cell line (Photograph taken using an Olympus IX51 
microscope). (B) Microscope image of the 786-O cell line (Cell Lines Service © CLS). (C) Microscope 
image of the and FG-2 cell line. (Cell Lines Service © CLS). 
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3.2 Establishment of an everolimus-resistant renal cell 
carcinoma cell line   
 
Firstly, a cryopreserved vial of the 786-O cell line was thawed. An everolimus-
resistant subline (786-OR) was generated upon exposure of the 786-O cell line to 
crescent concentrations of everolimus (Afinator® 10 mg - Novartis). One everolimus pill 
was diluted in 10.4 mL of DMSO (Dimethyl sulfoxide, SIGMA®) to obtain a 10mM 
stock solution. In terms of exposure times and everolimus concentrations, we adapted a 
previously established protocol for target therapy resistance induction in RCC cell lines 
[72]. Specifically, 15 days exposure to everolimus at 5µM, followed by 15 days 
exposure to everolimus at 10µM and finally 2 months exposure to everolimus at 20µM.  
In order to confirm that the resistance establishment was successful we 
performed a cell viability assay using Resazurin Sodium Salt (ACROS OrganicsTM – 
fisher scientific). Resazurin is a cell permeable redox indicator that can be used to 
monitor viable cells. Continued growth is associated with a reduced cell environment 
while inhibition of growth maintains an oxidized environment. The resazurin change 
from oxidized form (non-fluorescent, blue) to its reduced form resorufin (fluorescent, 
red) when it is observed a reduction of cell growth. The data regarding oxidized/reduced 
forms of resazurin can be collected using either fluorescence-based or absorbance-based 
methodology. Absorbance is monitored at 570nm and 600nm and was the method 
chosen for this work. The two variables that most affect the response of cells to 
resazurin are the length of incubation time and number of cells plated. The optimum 
plating density and incubation time should be determined for each cell line since each 
cell line presents distinct growth features. We determined both these variables for the 
786-O cell line, being the best plating density 40 000 cells/well and the best incubation 
time of 3 hours.  
After the protocol optimizations, we analyzed the cell viability of the 786-O and 
the established 786-OR cell lines in order to confirm the resistance acquisition 
phenotype to the everolimus resistance. In a 96-multi well plate, 40 000 cells/well of 
786-O and 786-OR were cultured in 8 wells each. After 24 hours, Resazurin was added 
to each well in a 10% proportion to the final volume. Absorbance’s were then measured 
at 570 nm and 600 nm upon 3h of Resazurin addition using a plate reader FLUOstar 
Omega, BMG Labtech, Offenburg, Germany. This experiment was performed at the end 
3. Material and Methods  
 
MicroRNA-101 as a potential regulator of mTORC2 and HIF-2a in renal cell carcinoma 
53 
of 15 days exposure to everolimus at 5µM, 15 days exposure to everolimus at 10µM and 
15 days exposure to everolimus at 20µM, 1 month exposure to everolimus at 20µM and 
at the end of the establishment of the everolimus-resistant renal cell carcinoma cell line. 
In order to calculate the percent difference in reduction of resazurin between 
treated (786-OR) and control cells (786-O) we used the following formula: 
 
 
 
 
 
 
 
 
  
Figure  11 – Formula to calculate the percent difference in reduction between treated and control cells 
in metabolic capacity experiment. eOX-molar extinction coefficient of Resazurin oxidized form; A- 
absorbance of test wells; Aº- absorbance of positive growth control well; l1- 570nm; l2-600nm. 
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3.3 MicroRNA and mRNA extraction and cDNA synthesis 
 
When the desired cell confluence was achieved (80-90%) the medium, in which 
the cells were being cultured, was collected for miRNA extraction and the cells were 
trypsinized, using 0.05 % trypsin-EDTA (1×) (Gibco®) and counted using 
EVE™ Automated Cell Counter (NanoEnTek®) and Tripan-Blue dye (Gibco®). After 
counting, approximately 2 million cells were centrifuged to form a pellet for either 
miRNA or mRNA extraction and the remaining cells were kept in culture.  
This procedure was repeated five times for each cell line and respective medium. 
Taking in consideration the 786-OR cell line, this procedure was performed at the end 
of the 15 days exposure to everolimus at 10µM and at the end of the establishment of 
the everolimus-resistant cell line. 
MicroRNA extraction (from the cells and respective medium) was performed 
using the GRS microRNA kit (Grisp®) and mRNA extraction (from the cells) was 
performed using the GRS Total Blood & Cultured Cells Kit (Grisp®), according to a 
procedure already optimized in our lab [68, 73].  
The miRNA samples were then used as templates for cDNA synthesis using a 
Taqman®MicroRNA Reverse Transcription kit (Applied Biosystems®) and sequence-
specific stem-loop primers for miRNA-101, RNU-44, RNU-48 and RNU-6B and the 
mRNA samples were then used for cDNA synthesis using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems®).  After protocol optimization, the 
thermal conditions were as follows: 16ºC for 30 min, followed by 42ºC for 60 min and 
85ºC for 10 min for miRNAs cDNA synthesis and 25ºC for 10 min, followed by 37ºC 
for 120 min and 85ºC for 5 min for mRNA.  
 
3.4 Real-time PCR relative quantification  
 
The miRNA and mRNA expression was analyzed by quantitative real-time PCR. 
The reactions were carried out on a StepOneTMqPCR Real-Time PCR and 
StepOnePlusTM qPCR Real-Time PCR machine, containing 1X Master mix (Applied 
Biosystems®), with 1X probes (TaqMan® microRNA Expression Assays, miRNA-101*: 
TM-002143, TaqMan® microRNA Control Assays, RNU-6B: TM-001093, RNU-48: 
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TM-001006 and RNU44: TM-001094 or TaqMan® mRNA Expression Assays, HIF-2a: 
HS01026149 and human GUSB (Beta Glucuronidase, (Applied Biosystems®) and a 
cDNA sample. RNU-6B, RNU-44 and RNU-48 were used and quantified to determine 
which one had the most constant expression levels in the microRNA tested samples to 
normalize results and function as endogenous control. According to a previous study 
from our group, GUSB was described as the best endogenous control for mRNA 
normalization in the same RCC cell lines [73]. Therefore, this endogenous control was 
used in the present study.  
According to Sarbassov et al and Masri et al, mTORC1 and mTORC2 
expression can be indirectly quantified. Thus, mTORC1 and mTORC2 can be 
represented by the mRNA expression of specific molecules of each complex, such as 
Raptor for mTORC1, Rictor for mTORC2 and mTOR is common to both complexes. 
The mTOR complexes were analyzed according to their relative levels of Raptor, Rictor 
and mTOR. Quantitation of the relative levels of cDNAs encoding mTOR, Rictor, 
Raptor and b-Actin (ACTB) was performed using Fast SYBR green master mix 
(Applied Biosystems®). b-Actin was used as an endogenous control to mRNA tested 
samples. The primer sequences used are presented in table 1 [74]. PCR conditions were 
as follows: 95ºC for 20s, 95ºC for 3s, 63,5ºC (mTOR)/64,5ºC (Rictor)/66ºC 
(Raptor)/63ºC (ACTB) for 30s, 95ºC for 15s, 60ºC for 1min and 95ºC for 15s.  
 
 
 
Table 1 – Primer sequence of mTOR, Rictor, Raptor and ACTB used in relative quantification with Fast SYBR 
green master mix.  
Gene Primer sequence 
mTOR 
5’-GAC TGC TTT GAG GTT GCT ATG AC-3’ 
5’-CCT TTG GTA TTT GTG TCC ATC AGC-3’ 
Rictor 
5’-AAC ACC AAG CAG GTT CAT GAA AGC-3’ 
5’-CAG ATG GAA GAC CTC CTG CAT CA-3’; 
Raptor 
5’-TGA CGG CCA CAG ACG ATG GTG CC-3’ 
5’-CGT AGG GAT GTC CTG CAC CTT CA-3’ 
b-Actin 
5’- CTA AGT CAT AGT CCG CCT AGA AGC A-3’ 
5’- TGC CAC CCA CGA CAA TGA A-3’ 
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Data analysis was performed using StepOneTM Sofware v2.2 (Applied Biosystems®) 
and the baseline and threshold were set for each plate to create threshold cycle (CT) 
values for all the miRNAs and mRNAs in each sample. All quantifications were 
performed in duplicate and each plate had a negative control.  
 
3.5 Statistical Analysis 
 
Statistical analysis was performed using IBM®SPSS®Statistics software for Windows 
(version 22.0). Livak method (2-ΔΔCt) and t´ student test was used to evaluate the 
differences in the expression levels of the normalized miRNAs and mRNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4. Results 
 
MicroRNA-101 as a potential regulator of mTORC2 and HIF-2a in renal cell carcinoma 
59 
4. Results 
4.1 Endogenous control selection for microRNAs relative 
quantification 
 
The graphs represented in figure 12 show the Ct (the cycle number at which the 
fluorescence generated within a reaction crosses the background fluorescence) mean 
value of RNU44, RNU48 and RNU-6B endogenous controls, both in cells 
(intracellular) and in culture medium (extracellular). The results show that RNU44 is 
the endogenous control that presents more constant and stable mean Ct values and 
smaller standard deviations. As so, RNU44 was the endogenous control chosen to 
normalize the miRNA expression levels in the present study.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure  12 – Mean Ct values of three human miRNAs endogenous controls analyzed in 
the three renal human cell lines used in the study (A, C and E) and in the corresponding 
culture medium (B, D and F). 
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4.2 MiRNA-101, HIF-2a, Rictor, Raptor and mTOR 
mRNA basal levels in HKC-8, 786-O and FG-2 cell lines  
 
Figure 13 shows the graphs representing the intra (A) and extracellular (B) 
levels of miRNA-101. According to the results, there is a significant difference in the 
intracellular levels of miRNA-101 when comparing HKC-8, 786-O and FG-2 cell lines. 
In fact, it has been observed a fold-decrease of 0.36 in the 786-O cell line compared to 
HKC-8 (fold change= 0.36, P=0.030). The same tendency is observed when comparing 
HKC-8 and FG-2 cell lines, with a fold change of 0.26 in the FG-2 cell line (fold 
change= 0.26, P=0.003) (Figure 13 A). 
Regarding the extracellular levels, the expression of the miRNA-101 is 
significantly higher in FG-2 medium (fold change=46.21, P<0.001) and present a 
tendency to be higher in 786-O medium (fold change=3.16, P=0.052) compared to the 
HKC-8 cell medium (Figure 13 B).  
 
 
 
Figure  13 – MiRNA-101intracellular (A) and extracellular (B) expression levels in 786-O and FG-2 cell lines 
compared to HKC-8 cell line.   
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 Regarding the HIF-2a mRNA expression levels, we observed significantly 
higher levels of this transcript in 786-O (fold change= 10.1, P<0.001) and in FG-2 (fold 
change= 1.72, P=0.016) when compared with HKC-8 cell line (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 shows the graphs representing the mTOR, Raptor and Rictor mRNA 
levels. According to the results, there is also a significant difference in mTOR mRNA 
levels between HKC-8 and 786-O cell lines, with a fold-increase of 5.46 in 786-O cell 
line (fold change= 5.46, P<0.001). However, there is no statistical significant difference 
in mTOR mRNA levels in HKC-8 versus FG-2 cell lines (fold change= 0.37, P=0.057) 
(Figure 15A).   
Regarding the Raptor mRNA levels, we observed significantly higher levels of 
this transcript in 786-O cell line (fold change= 9.99, P<0.001) when compared with 
HKC-8 cell line. However, there is no statistical significant difference in Raptor mRNA 
levels between HKC-8 and FG-2 cell lines (fold change= 2.60, P=0.08) (Figure 15B).  
According to the results, there is also an increase of Rictor mRNA in 786-O cell 
line with a fold-increase of 3.36 when compared with HKC-8 (fold change= 3.36, 
P<0.001). Regarding the FG-2 cell line there is a decrease of Rictor mRNA expression 
when compared with HKC-8 (fold change= 0.29, P=0.031) (Figure 15C).  
Figure  14 – HIF-2a mRNA levels change in 786-O and FG-2 cell lines compared to HKC-8 cell line.  
4. Results 
 
MicroRNA-101 as a potential regulator of mTORC2 and HIF-2a in renal cell carcinoma 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  15 – mTOR (A), Raptor (B) and Rictor (C) mRNA levels variation in 786-O and FG-2 cell lines compared to HKC-8 cell line.  
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4.3 Characterization of an everolimus-resistant RCC cell 
line 
 
In figure 16 is represented the graph describing the difference in resazurin 
reduction capacity between everolimus treated cells (786-OR) and control cells (786-O) 
at different time points.   
According to the results, at the end of 15 days of exposure to 5µM of 
everolimus, there were no differences in cell viability between 786-O and 786-OR. 
However, at the end of 15 days of exposure to 10µM of everolimus there was a decrease 
of 30% of metabolic capacity in the 786-OR comparatively to 786-O cells. However, 
after this time period at 10µM of everolimus exposure, the 786-OR cells started to 
recover their metabolic capacity and reached the 100% of metabolic capacity after 15 
days of exposure to everolimus at a concentration of 20µM. After that time point, the 
786-OR cells were able to maintain their metabolic capacity during 2 months in same 
exposure conditions, which indicates that the cells successfully developed resistance to 
everolimus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  16 – Metabolic capacity of 786-OR cells at different 
time points submitted to different everolimus concentrations.  
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In figure 17, the microscope images of 786-O (Figure 17A) and 786-OR (Figure 
17 B-F) shows morphological changes at different stages of resistant phenotype 
establishment. There is a significant difference in 786-OR morphology after 15 days of 
exposure to everolimus at 5µM (Figure 17B) and the same difference remains after 15 
days of exposure to everolimus at 10µM (Figure 17C) and after 15 days of exposure to 
everolimus at 20µM (Figure 17D) when compared with control cells. After 1 month of 
exposure to everolimus at 20µM the cells begin to acquire their normal morphology 
(Figure 17E). Finally, after 2 months of exposure to everolimus at 20 µM, 786-OR 
seems to have the same morphology as 786-O (Figure 17F).   
 
 
 
 
 
 
 
 
 
 
Figure  17 – Microscope images of 786-O (A) cells and treated cells (786-OR) (20x) at different everolimus 
concentration and time points. (B) 786-OR after 15 days of exposure to everolimus at 5µM. (C) 786-OR after 15 days 
of exposure to everolimus at 10µM. (D) 786-OR after 15 days of exposure to everolimus at 20µM. (E) 786-OR after 
1 month of exposure to everolimus at 20µM. (F) 786-OR after 2 months of exposure to everolimus at 20µM. 
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4.4 786-OR cell line: MiRNA-101, HIF-2a, Rictor, Raptor 
and mTOR mRNA levels  
 
Figure 18 shows the intracellular (A) and extracellular (B) levels of miRNA-101 
in 786 cell line during the acquisition of everolimus resistance. According to the results, 
there is no statistical significant difference in 786-OR after 15 days of exposure to 
everolimus at 10µM (fold change= 0.42, P=0.115) and present a tendency to be lower in 
786-OR after 2 months of exposure to everolimus at 20µM (fold change= 0.33, 
P=0.064) (Figure 18A).  
Regarding the extracellular levels, when compared with the miRNA-101 levels 
in 786-O medium with 786-OR medium after 15 days of exposure to everolimus at 
10µM there is no statistical significant difference (fold change= 0.62, P=0.557). 
However, the expression of miRNA-101 is significantly higher in 786-OR medium after 
2 months of exposure to 20 µM everolimus when compared to the 786-O medium, with 
a 11.63 fold-increase in expression levels (fold change=11.63, P=0.004) (Figure 18B).  
 
 
 
 
 
 
 
 
Figure  18 – Variation of the intracellular (A) and extracellular (B) expression levels of miRNA-101 in 786-O, 786-
O after 15 days of exposure to everolimus at 10µM and 786-O after 2 months of exposure to everolimus at 20µM. 
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Regarding the HIF-2a mRNA expression levels, we observed that after 15 days 
of exposure to everolimus at 10µM there was a decrease of HIF-2a mRNA expression 
in 786-OR (fold change= 0.29, P=0.005) when compared with 786-O. However, we 
observed an increase of HIF-2a expression in 786-OR after 2 months of exposure to 
everolimus at 20µM (fold change= 2.83, P=0.003) when compared with 786-O (Figure 
19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 represents the mTOR mRNA relative expression levels at different 
time points of 786-OR establishment. According to the results, there is no statistical 
significant difference between 786-O and 786-OR after 15 days of exposure to 
everolimus at 10µM (fold change= 1.31, P=0.083) and after 2 months of exposure to 
everolimus at 20µM (fold change= 1.02, P=0.450). 
 
 
 
 
 
 
 
 
 
 
 
Figure  19 –  Variation of the relative expression levels of HIF-
2a mRNA in 786-O, 786-O after 15 days of exposure to 
everolimus at 10µM and 786-O after 2 months of exposure to 
everolimus at 20µM. 
Figure  20 – Variation of the relative expression levels of 
mTOR mRNA in 786-O, 786-O after 15 days of exposure to 
everolimus at 10µM and 786-O after 2 months of exposure to 
everolimus at 20µM. 
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 Regarding the Raptor mRNA relative expression, it is significantly lower in 786-
OR after 15 days of exposure to everolimus at 10µM (fold change= 0.08, P=0.001) and 
after 2 months of exposure to everolimus at 20µM (fold change= 0.22, P<0.001) when 
compared with 786-O cell line (Figure 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In figure 22, it is represented the Rictor mRNA relative expression levels. 
According to the results, there is a decrease in 786-OR after 15 days of exposure to 
everolimus at 10µM (fold change= 0.04, P<0.001) and after 2 months of exposure to 
everolimus at 20µM (fold change= 0.08, P=0.003) when compared with 786-O cell line.  
 
 
Figure  21 – Variation of the relative expression levels of Raptor 
mRNA in 786-O, 786-O after 15 days of exposure to everolimus at 
10µM and 786-O after 2 months of exposure to everolimus at 
20µM. 
Figure  22 – Variation of the relative expression levels of Rictor 
mRNA in 786-O, 786-O after 15 days of exposure to everolimus at 
10µM and 786-O after 2 months of exposure to everolimus at 20µM. 
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5. Discussion  
 
ccRCC is a neoplasia that presents an aggressive cell phenotype and a high 
potential to metastasize due to its intense vascularity and to the overexpression of 
angiogenic factors [13]. One of the major signaling pathways deregulated in ccRCC is 
the PI3K/AKT/mTOR pathway [75]. This pathway is responsible for several 
physiological functions, including cell cycle, cell survival, protein synthesis, growth, 
metabolism, motility and angiogenesis [76, 77].  
In the recent years, the discovery of the pathways involved in ccRCC 
pathogenesis allowed the development of targeted therapies directed to these pathways 
[41, 78]. One example, it is the everolimus, an mTOR inhibitor used in the treatment of 
ccRCC patients that present a worse prognosis [26]. This agent forms a complex with 
the FK binding protein and inhibits mTORC1 [75]. However, despite the improvement 
in ccRCC outcomes achieved by this targeted therapy, the control of this disease is 
time-limited, mainly in consequence of the acquisition of resistance to this therapy [40, 
79]. Taking this into account, the need of new, effective and predictive biomarkers 
increase. These biomarkers would be important to predict which patients will develop 
resistance to these targeted therapies and consequently disease progression, allowing in 
the future changings in the therapeutic approaches, with a significant impact in patients’ 
clinical outcomes. Since miRNAs are key elements in the regulation of gene expression 
and because they present a different expression patterns in normal and tumoral tissues, 
and during the disease progression, they can be used as potential biomarkers in this field 
[70, 80].  
Several studies describe the miRNA-101 as a tumor suppressor miRNA, and as 
down-regulated in many solid cancers, including hepatic, pancreatic, lung and prostate 
cancer [69]. In ccRCC, two studies reported its downregulation in cancer cell lines 
when compared with a normal epithelial kidney cell line [71, 81]. These results are 
consistent with the results found in the present study, since miRNA-101 is significantly 
decreased in 786-O and FG-2 cell lines when compared with HKC-8. Additionally, the 
circulating levels of specific miRNAs are promising noninvasive blood-based 
biomarkers with a high potential for the early RCC diagnosis and for the monitorization 
of therapy response. However, there are still no studies reporting miRNA-101 
extracellular levels in ccRCC. In fact, we observed for the first time an increased 
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expression of miRNA-101 in the cell medium of both ccRCC cell lines, which suggests 
the secretion of this miRNA to the surrounding extracellular environment. Taking this 
data into account, we hypothesize that, in addition to a decrease in miRNA-101 
production by ccRCC cancer cells, the cells may also increase the excretion of this 
miRNA to the cellular microenvironment. The miRNA-101 excretion, and consequent 
uptake by the tumor neighbor cells, will result in this miRNA influencing its 
proliferation suppression functions on these cells, which ultimately will result in a 
proliferative advantage to the tumor cells. 
Since miRNA-101 targets DNA-PKcs, which positively regulates mTORC2 and 
AKT activation, when miRNA-101 is downregulated there is a downstream activation 
of PI3K/AKT/mTOR signaling pathway, including mTORC2, which lead to cell 
survival and proliferation [71]. An indirect method for either mTORC1 and mTORC2 
expression levels analysis was proposed by Sarbassov et al and Masri et al [82, 83]. In 
this method, mTORC1 and mTORC2 expression can be associated with the mRNA 
expression of specific molecules of each complex, such as Raptor for mTORC1 and 
Rictor for mTORC2. Thus, since the mTOR is common to both complexes, we can 
assume that, when we have higher levels of Raptor, we have a higher expression of 
mTORC1 and when we have higher levels of Rictor, we have a higher expression of 
mTORC2.  
According to our study, we observed an increase of Rictor expression in 786-O 
when compared with HKC-8, meaning an increased mTORC2 expression. This is 
supported by the constitutive hypoxic state described for this cell line, due to the 
constitutive expression of HIF-2a, since mTORC-2 activates the HIF-2a transcription 
and consequently the protein expression [84, 85]. However, the expression of Rictor is 
decreased in FG-2 cell line when compared with HKC-8 and 786-O cell lines. As so, 
what we propose is that in FG-2 cell line there is a lower expression of mTORC2 
probably due to the tendency of mTORC1 upregulation. Regarding Raptor expression, 
we observed an upregulation of its mRNA in 786-O when compared with HKC-8. As 
so, we can infer that mTORC1’ expression is increased in this tumor cell line. These 
deregulations were accompanied by the increase of mTOR levels in 786-O cell line 
when compared with HKC-8 and FG-2 cell lines. These facts validate that the 
upregulation of either mTORC1 and mTORC2 is a key contributor to the malignancy 
and more aggressive phenotype of ccRCC. 
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In order to clarify the role of both mTORC2 and miRNA-101 in the 
development of resistance to mTOR inhibitors an everolimus-resistant cell line (786-
OR) was established. We verified a decreased expression of miRNA-101 intracellular 
levels in 786-OR when compared with 786-O, accompanied by an increase of its 
extracellular levels. As so, what we propose is that besides a decrease in miRNA-101 
production by everolimus-resistant cell line, there is also an increase of this miRNA 
excretion. These results are very interesting and highlight the potential use of miRNA-
101 as noninvasive blood-based biomarker specifically for the monitorization of 
mTOR-inhibitors therapy response in ccRCC patients. 
In our in vitro study, everolimus had an effect in mTORC1 expression since the 
Raptor mRNA expression decreased in 786-OR cell line along with the acquisition of 
everolimus resistance when compared with control cells (786-O). When trying to 
explain the mechanisms of resistance to everolimus, several researchers propose that the 
resistance to mTOR inhibitors can be explained by a compensatory activation of 
PI3K/AKT pathway via the upregulation of mTORC2 [86]. However, in our study, we 
observed that Rictor is significantly decreased in 786-OR cell line. Moreover, regarding 
the mTOR expression, our results show that mTOR levels remain approximately the 
same along the acquisition of resistance to everolimus.  
The decrease in Rictor expression, and consequently of mTORC2, suggests that 
the resistance to mTOR inhibitors may not be exclusively dependent of the upregulation 
of this molecule but can be supported by the overexpression of other pathways, such as 
HIF-2a pathway. Upon activation, HIF-2a translocate to the nucleus and regulates the 
expression of a wide range of genes implicated in tumorigenesis [28]. In fact, we 
observed that both tumoral cell lines the 786-O and FG-2 presented an increase of HIF-
2a expression levels when compared with normal cell line HKC-8. These results 
suggest that HIF-2a has tumorigenic activity in ccRCC. Furthermore, according to our 
study, HIF-2a is significantly increased in 786-OR cell line when compared with 786-O 
cell line. As so, what we propose is that the resistance to mTOR inhibitors can be 
supported by the overexpression of HIF-2a, which can lead to activation of several 
pathways related with cell survival and proliferation. Chengxing and colleagues, 
showed that HIF-2a directly and indirectly promotes proliferation through the mitogen-
activated protein kinase (MAPK) pathway [87]. Additionally, the PI3K pathway and the 
MAPK pathways share common upstream activators and these pathways are 
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significantly interconnected by feedback loops. One pathway provides compensatory 
signaling when the other is inhibited [88]. Arkaitz Carracedo and colleagues showed 
that in conditions of mTORC1 inhibition, Ras is activated and signals to MAPK 
pathways [89, 90]. As so, the upregulation of MAPK pathways may be related with 
acquired resistance to mTOR inhibitors. 
The results of the present study demonstrate that everolimus inhibits mTORC1 
and affect the mTORC2 expression. On the other hand, the development of everolimus 
resistance results in HIF-2a pathway upregulation in ccRCC resistant cell line (Figure 
23). Moreover, the results suggest that miRNA-101 is a potential predictive biomarker 
of resistance to mTOR inhibitors since this miRNA is excreted by the resistant cells’ to 
everolimus (Figure 23). Additionally, the excretion of this miRNA was observed at the 
end of 3 months while the resistance to mTOR inhibitors in patients, which is detected 
by disease progression, only was observed at the end of 6-15 months [44]. As so, the 
circulating levels of miRNA-101 may allow an improvement in the monitorization of 
everolimus resistance acquisition and in the future new therapeutic approach. Since 
alterations in this miRNA expression can be detected early, this miRNA can be applied 
to the clinical practice without a painful procedure to the patient.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  23 – Proposed model of PI3K/AKT/mTOR and HIF-2a pathways regulation in the 
development of resistance to mTOR inhibitors in RCC and the role of miRNA-101 during the 
acquisition of resistance, according to the results obtained in the present study. 
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6. Conclusion and Future Perspectives 
 
The use of targeted therapies directs to key molecules involved in RCC 
development has been revolutionizing cancer treatment, however these therapies have 
limitations mainly due to the acquisition of resistance to them. 
Everolimus, an mTOR inhibitor, inhibits the activation of mTORC1 which can 
lead to a compensatory activation of PI3K/AKT pathway, which potentially can drive 
resistance via upregulation of mTORC2. According to our in vitro study, the resistance 
to mTOR inhibitors seems not to be related with overexpression of mTORC2, since this 
complex is downregulated in the resistant cell line established in this study. In fact, the 
downregulation of mTORC2 suggests that the resistance to mTOR inhibitors may not 
be exclusively dependent of the upregulation of this complex but can be supported by 
the overexpression of other pathways, such as HIF-2a pathway, observed in this study. 
As so, it would be interesting in the future to study another pathway’s related to the 
upregulation of HIF-2a, such as the MAPKs pathway. In addition, it would be useful to 
quantify the protein levels of the corresponding mRNAs quantified in the present study 
and other proteins that comprises the complexes, mTORC1 and mTORC2, in order to 
replicate and validate the results obtained.  
MiRNAs may be useful biomarkers to predict targeted therapies resistance since 
they regulate gene expression of different molecules involved in crucial cellular 
processes and they are easy to quantify using biological samples. MiRNA-101, which 
indirectly and positively regulates the mTORC2 activation, seems to be an important 
regulator of resistance to mTOR inhibitors.  In fact, we have found that miRNA-101 
expression is deregulated in ccRCC.  
This deregulation seems to be established not only by a decrease in the 
production of miRNA-101 but also by an increase of its excretion in ccRCC cell lines. 
These results, were also observed in everolimus-resistant cell line. The deregulation of 
this miRNA and the increase of its excretion in resistant cell line defines it as possible 
circulating biomarker and offers the possibility to use the miRNA-101 as potential 
predictive biomarker of resistance to mTOR inhibitors.  
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According to our results, in the future, it is important to replicate the study in 
vivo, in order to validate the potential of miRNA-101 as circulating biomarker in the 
clinical practice. In the future studies, it would also be useful to understand what are the 
differences in the miRNA-101 expression levels of ccRCC patients before initiating 
therapy with mTOR inhibitors and monitor their expression along the treatment. This 
would help to clarify the role of this miRNA as possible biomarker, allowing the 
monitoring of response to therapy predicting the resistance. Additionally, it would be 
interesting to search for more deregulated miRNAs in ccRCC, related with these 
pathways in order to establish a miRNA profile.  
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Renal cell carcinoma (RCC) is the most commonly occurring solid cancer of the adult kidney with the ma-
jority of RCC cases being detected accidentally. The most aggressive subtype is clear cell RCC (ccRCC). miR-
NAs, a family of small noncoding RNAs regulating gene expression have been identified as key biological
modulators. The von Hippel–Lindau pathway is one of the signaling pathways involved in the pathophys-
iology of ccRCC. Another oncogenic mechanism involves the activation of PI3K/AKT/mTOR signaling and
serves as a central regulator of cell metabolism, proliferation and survival. Several studies have described
the involvement of miRNA dysregulation in the pathogenesis and progression of ccRCC. These molecules
can be considered as potential diagnostic and prognostic biomarkers, allowing response to therapy to be
monitored.
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Renal cell carcinoma (RCC) is the most common renal malignancy, representing approximately 2% of all cancers,
and it is the most lethal urological cancer. Kidney cancer accounts for approximately 84,000 new cases and 35,000
deaths in Europe every year. There is a 2:1 male predominance, with a peak incidence between 60 and 70 years [1].
RCC is a heterogeneous cancer which is divided into various subtypes, each derived from a different part of
nephron with different genetic and molecular alterations, histological features, clinical phenotypes and prognosis.
The major subtypes are the clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC) [2].
The most common subtype of RCC is ccRCC, which accounts for approximately 80% of all cases, and it is
characterized histologically by high cell lipid content and a richly vascularized tumor stroma [3]. ccRCC is the
most aggressive subtype and it is associated with a high risk of metastasis formation, since most cases are not
detected during the early stages [4]. Localized ccRCC can be treated with surgery, however, approximately 30% of
these patients eventually develop metastases, which are associated with high mortality rates [1]. In consequence of
the highly vascular nature, ccRCC rapidly becomes chemo- and radioresistant leading to a poor prognosis, thus
requiring the development of new therapies or new therapeutic schemes [5].
Increasing molecular knowledge regarding the key signaling pathways deregulated in ccRCC has allowed, in
recent years, the development of new target therapies [6]. The von Hippel–Lindau (VHL) pathway is one of the
major signaling pathways involved in the pathophysiology of ccRCC. The protein encoded by the VHL gene,
under normoxic conditions, serves as a recognition site for the regulatory subunits of HIF, targeting them with
ubiquitin to proteasome degradation. In consequence of the alterations of VHL, due to the loss of the short
arm of chromosome 3, or its inactivation or mutation, HIF degradation stops leading to its accumulation in the
cytoplasm and migration to the nucleus. Here, it binds to hypoxia-related genes, resulting in a cell hypoxic response
under normoxic conditions. These alterations lead to the transcriptional activation of genes involved in pathways
responsible for angiogenesis and cell growth, such as the transcription of PDGF and VEGF [7].
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Another ccRCC oncogenic mechanism involves the activation of the mTOR pathway, a recurrent oncogenic
event in cancer [8]. The mTOR protein is a highly conserved serine/threonine kinase that belongs to the PI3K-
related kinase family. Through both intracellular and extracellular signaling, the mTOR pathway plays a role in
the regulation of cell metabolism, growth, proliferation and survival [9]. mTOR is a downstream effector of the
PI3K/AKT pathway and is also activated by genetic alterations that reduce the function of the tumor-suppressor
PTEN or increase the function of the catalytic subunit of PI3K leading to abnormal activation of AKT. In addition,
it has been elucidated that HIF protein expression is dependent of mTOR [10]. The discovery of the VEGF
and mTOR involvement in ccRCC pathogenesis allowed the development of targeted therapies directed to these
pathways [6].
There are two major types of targeted agents used in ccRCC treatment according to the key pathways deregulated:
angiogenesis inhibitors that target the VEGF ligand or VEGF receptors (VEGFR; such as the multikinase inhibitors
axitinib, sunitinib, pazopanib and sorafenib) and inhibitors of the mTOR signaling pathway (everolimus and
temsirolimus) [2,11].
Additionally, cytokine therapies (IL-2 and IFN-α) constitute an interesting alternative to the standard metastatic
ccRCC treatment. IFN-α and/or IL-2 that activate diverse immune effector cells have improved disease control rates
and clinical outcomes. However, the significant toxicities of cytokines and the fact that they present less clinical
efficacy when compared with tyrosine kinase inhibitors (TKIs) limits the use of these therapies [12]. Currently,
targeted therapies have become the standard treatment for patients with metastatic RCC, replacing the cytokine
therapies [13].
More recently, a new treatment approach has been developed, which modulates the immune system against
tumor cells. This treatment targets the PD-1 receptor and PD-L1, leading to inhibition of the PD-1 checkpoint
pathway. The development of targeted treatments has led to an improvement in RCC treatment outcomes, but
fails to cure the disease mainly due to the development of resistance [14].
Additionally, several questions remain unanswered with regard to the optimal use of these agents, including
the most effective sequence of targeted therapies, the benefits of targeted therapies in combination and how to
overcome resistance development to these agents. It is important to note that, despite the prognosis improvement of
metastatic ccRCC patients, the response to targeted therapies is varied and the majority of patients will eventually
progress in the disease. Currently, no curative treatment for metastatic ccRCC is available [15].
Resistance to target therapies in RCC
The targeted agents approved for ccRCC treatment have increased progression-free survival and overall survival
in the majority of patients [16]. However, these treatments have specific toxicity profiles, which can lead to dose
reduction and even discontinuation of the treatment [17]. Additionally, the development of resistance also led to
changes in dosing schedules in order to overcome the failures of first-line therapies and, currently, most of the
therapeutic approaches include several lines of treatment per patient. Resistance is currently defined by the evidence
of disease progression. This raises a clinical and scientific question regarding the mechanisms of resistance to TKIs
and mTOR inhibitors [18]. In terms of therapy response, Ravaud et al. divided the patients into three groups. One
subset of patients, approximately 25%, demonstrated resistance to therapy when they were initially assessed for
response following 2–3 months of therapy. A larger group of patients showed initial tumor regression, followed by
a short period of disease stability, and finally disease progression after 6–12 months of treatment. The third subset
of patients experienced tumor regression in the first few months of therapy followed by a longer period of disease
stability with no appearance of new lesions [19].
Drug resistance in ccRCC occurs to allow the survival of cancer cells and it is observed with the currently
used targeted therapies such as VEGFR and mTOR inhibitors. The resistance to VEGFR inhibitors is often
due to mutation in a gene encoding a key receptor tyrosine kinase. However, these mutations would have to
take place in the tumor endothelium, which is the main target of VEGFR inhibitors and it is almost impossible
that identical mutation coexists on each individual tumor metastasis. Another potential mechanism of resistance
is upregulation of alternative proteins and/or pathways that re-establish angiogenesis and growth capacity in a
VEGF-independent manner [18]. For example, upregulation of angiopoietin 2, c-MET or IL-8 signaling can trigger
alternative angiogenesis, whereas the proliferation can be promoted through upregulation of the PI3K/AKT/mTOR
pathway [8]. Other resistance mechanisms involve the occurrence of an increased drug efflux that results in decreased
intracellular TKI concentrations in cells. TKIs are captured and stored in intracellular compartments instead of
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reaching cancer cells promoting low concentrations in plasma and serum. Promotion of inflammation is another
mechanism of resistance. Bone marrow-derived cells modulate expression of a wide variety of cytokines, growth
factors and enzymes promoting tumor adaptation and resistance to targeted therapies [20].
mTOR inhibitors form a complex with the FK binding protein and inhibit mTOR from binding complex
1 (mTORC1). However, the other mTOR complex, mTOR complex 2 (mTORC2) may not be inhibited by
these targeted therapies. These facts suggest that inhibition of mTORC1 leads to a compensatory activation of
PI3K/AKT pathway via upregulation of mTORC2. mTORC2 activates AKT and HIF-2α, limiting the effect of
these therapies [14].
This suggests that further investigation of the molecular pathology of RCC is needed which may then lead to
the identification of potential biomarkers that are predictive of tumor sensitivity to PI3K/AKT/mTOR-targeted
therapies. It is also important to identify new targets in order to develop new treatments. Several studies described
the involvement of miRNAs dysregulation in the pathogenesis and progression of ccRCC [21]. The cellular effects
of miRNAs dysregulation are diverse and often lead to typical hallmarks of cancer. These small molecules can
be considered as potential diagnostic and prognostic biomarkers, allowing the monitoring of disease, as well as
promising new therapeutic agents [14].
miRNAs
miRNAs are a class of short ncRNA molecules (∼22 nucleotides of length) that regulate gene expression at the
post-transcriptional level, through binding to the complementary region of corresponding mRNAs targets, leading
to the inhibition or degradation of mRNAs [22]. Most primary transcripts of miRNAs are produced in the nucleus.
Primary miRNAs (pri-miRNA) are transcribed by RNA polymerase II and are processed by Drosha and its cofactor
DGCR8, creating a pre-miRNA. The pre-miRNAs are carried out to the cytoplasm by the XPO5, where it is
cleaved by Dicer to generate the mature double-stranded miRNA. The mature miRNAs are incorporated into the
RNA-induced silencing complex, which will guide them to the complementary region of their targets and this
process results in the inhibition of mRNA translation, or promotes its degradation and leads to post-transcriptional
gene silencing [23].
Recent publications suggest that miRNAs have an important role in cancer development by influencing all cancer
hallmarks, which include: resistance to cell death, genome instability and mutation, induction of angiogenesis,
activation of invasion and metastasis, tumor-promoting inflammation, replicative immortality capacity, avoid to
the immune destruction, evading growth suppressors, sustaining proliferative signaling and deregulating cellular
energetics [24].
miRNAs may have more than one target while different miRNAs can interact with the same mRNA. Several
studies have shown that miRNAs are expressed or inhibited in different types of cancer, suggesting that miRNAs
work as onco-miRNA or tumor-suppressor miRNA. Through miRNA expression profiling analysis onco-miRNAs
which downregulated tumor suppressor genes and are overexpressed in cancer cells were identified [23]. For example,
Yu et al. showed that miR-7 expression increases significantly in RCC compared with normal adjacent tissues
and miR-7 serum levels from RCC patients were higher than in healthy individuals [25]. Other studies identified
tumor-suppressor miRNAs that are underexpressed in cancer. Zhu et al. compared miR-451 levels in RCC tissues
and in the corresponding adjacent normal tissues and showed that miR-451 levels in RCC tissues were lower than
in normal tissues [26]. Recent studies identified a number of miRNAs that are deregulated in ccRCC, which can be
used as potential biomarkers for early cancer diagnosis and prognosis, as well as potential targets for more efficient
treatments [23,27].
The circulating levels of specific miRNAs are promising noninvasive blood-based biomarkers with a high
potential for the early diagnosis of RCC and monitoring of therapy response since they may be predictive of
resistance therapies. According to a previous publication from our group, the increased miR-221 levels play a
key role in cellular microenvironment, modulating important cellular processes involved in carcinogenesis and
cancer progression. We also observed that RCC patients and healthy individuals have different expression levels of
circulating miR-221 [28].
Recent research data suggest that miRNAs may be also related to resistance to conventional therapies. Goto et al.
demonstrated that miR-101 exhibits antitumor activity and is significantly suppressed in sunitinib-treated RCC
tissues compared with the primary RCC tissues [29].
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Figure 1. Schematic representation of the miRNAs that are involved in the regulation of PI3K/AKT/mTOR pathway in cancer.
PI3K/AKT/mTOR pathway
The PI3K pathway is a signal transduction cascade that is responsible for many physiological functions, including
cell cycle, cell survival, protein synthesis and growth, metabolism, motility and angiogenesis (Figure 1). The
PI3K family is divided into four different classes: class I, class II, class III and class IV. Class I are heterodimeric
molecules composed by a regulatory subunit: PIK3R1, PIK3R2 and PIK3R3 and a catalytic subunit: PIK3CA,
PIK3CB and PIK3CD. The class IV is composed by ATM, DNA-PKcs and mTOR [30]. PI3K converts its substrate
phosphatidylinositol 4,5-biphosphate–PI (4,5) P2 into PI (3,4,5) P3 (or PIP3). However, PTEN antagonizes PI3K
activity and negatively regulates AKT signaling. Protein kinase B, also known as AKT, is a serine/threonine-specific
protein kinase, which is involved in multiple cellular processes. AKT can appear in one of three isoforms (AKT1,
AKT2, AKT3) [9].
PDK1 is recruited to the membrane and phosphorylates AKT at Ser308 and mTORC2 phosphorylates AKT at
Ser473 promoting full activation of AKT. AKT inhibits through phosphorylation TSC1/2. TSC1/2 functions as
a GAP and that way negatively regulates mTORC1 signaling by converting Rheb into its inactive form. The active
form of Rheb directly interacts with mTORC1 to stimulate its activity [31].
mTOR acts as a downstream effector of the PI3K/AKT pathway and is the catalytic subunit of the two
biochemically distinct complexes, mTORC1 and mTORC2. mTORC1 has five components: mTOR, which is the
catalytic subunit of the complex; rRaptor; mLST8 (also known GβL); PRAS40 and Deptor. mTORC2 comprises
six different proteins, of which some are common to mTORC1: mTOR; Rictor; mSIN1, Protor-1; mLST8 and
Deptor [10]. Each complex has a distinct protein composition, reflecting differences in upstream signal integration,
substrate regulation and biological process control. mTORC1 is regulated by nutrients, growth factors, cellular
energy and stress pathways, while mTORC2 is primarily regulated by growth factors. mTORC1/2 are both
positively regulated by IFNs. The mTOR complexes have distinct functions. mTORC1 has a positive regulatory
effect on cell growth and proliferation through the promotion of many anabolic processes, including biosynthesis
of proteins, lipids and organelles and by limiting catabolic processes such as autophagy. mTORC2 plays key roles
10.2217/pgs-2017-0160 Pharmacogenomics (Epub ahead of print) future science group
miRNAs as potential regulators of mTOR pathway in renal cell carcinoma Review
miR-155
miR-21
miR-126
miR-3151
miR-7
miR-375
miR-1
miR-132
miR-511
miR-125b
miR-663
miR-30b
miR-30a
miR-203
miR-101
miR-421
miR-185
miR-542-3p
miR-99a
miR-137
miR-302b
miR-184
miR-144
miR-489
miR-122
PI3K
PIP2
PIP3
AKT
TSC2
TSC1miR-451
miR-155 Rheb
mTOR
mTOR
Raptor
Deptor mLST8
PRAS40
mTORC1
mTORC2
HIF-1α
HIF-2α
miR-100
miR-221
miR-155
miR-218
miR-451
miR-496
miR-7
miR-99a
miR-101
miR-153
miR-214
miR-93
miR-152
miR-221
miR-130b
miR-103
miR-21
miR-193a-3p
PTEN
Protor-1
mSIN1
mLST8
Deptor
Rictor
Figure 2. Schematic representation of the miRNAs that are involved in the regulation of PI3K/AKT/mTOR pathway in cancer.
in various biological processes, including cell survival, metabolism, proliferation and cytoskeleton organization.
mTOR signaling is often deregulated in ccRCC, which can lead to an upregulation of HIF and a worse prognosis
for the patients [9].
miRNAs & PI3/AKT/mTOR pathway in cancer
The PI3K/AKT/mTOR pathway, a vital signal transduction system-linking oncogenes and multiple receptor
classes to several essential cellular functions, is perhaps the most commonly activated signaling pathway in human
cancer. Nowadays, it is known that miRNAs have an important role in regulation of mTOR signaling in most
cancer types.
In Figure 2, we summarize all the currently known miRNAs, with regulatory functions in the PI3K/AKT/mTOR
pathway that were described as deregulated in cancer.
Evidence acquisition
A systematic literature search of PubMed was conducted using the following keywords: miRNAs, PIK3R1, PIK3R3,
PIK3CA, PIK3CD, ATM, DNA-PKcs, PTEN, TSC1, TSC2, mTOR, AKT1, AKT2, AKT3, Rheb, Rictor. The
articles were selected by relevance of their findings. All the references of the cited papers were reviewed and relevant
publications in the field of PI3K/AKT/mTOR signaling involving the studied molecules were added.
Evidence synthesis
Investigations have shown that PIK3R1 (p85α), as negative regulator of the PI3K/AKT pathway, is a direct target
of miR-155 and miR-21. In fact, Huang et al. found that, in diffuse large B-cell lymphoma cell lines and in blood
samples, the overexpression of miR-155 leads to the downregulation of PIK3R1-activating AKT signaling [32].
Studies on breast and pancreatic cancers also showed that miR-21 and PIK3R1 expression are inversely correlated
promoting cell growth, migration and invasion [33,34].
Recent findings have shown that miR-3151 inhibits the PI3K/AKT pathway by repressing PIK3R2 in chronic
lymphocytic leukemia-inhibiting cell proliferation and enhancing apoptosis [35]. Studies in esophageal squamous cell
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carcinoma and bladder cancer have demonstrated that PIK3R2 is a direct target of miR-126-inhibiting proliferation,
migration, invasion and promoting apoptosis [36,37].
Other studies have shown that PIK3R3 is a target gene of miR-132 and miR-511. Overexpression of these two
miRNAs inhibits PIK3R3 expression and PI3K/AKT signaling activation. These findings showed that miR-132 and
miR-511 function as tumor suppressors in hepatocellular carcinoma. These miRNAs can inhibit cell proliferation,
migration and invasion and induced cell apoptosis in hepatocellular carcinoma [38,39].
Yu et al. showed that miR-1 is a potential tumor suppressor by targeting PIK3CA in non-small-cell lung cancer
(NSCLC) cell lines. Its repression of PIK3CA expression may play an important role in NSCLC progression [40].
Studies in human colorectal cancer and osteosarcoma identified miR-375 as a tumor growth suppressor through
repression of PI3K/AKT pathway by inhibiting PIK3CA [41,42].
Studies have shown that PIK3CD is a direct target of several miRNAs. Fang et al. showed that miR-7 regulates
cell proliferation and metastasis formation through the PI3K/AKT pathway and these findings were observed in
hepatocellular carcinoma [43]. Studies in colorectal cancer demonstrated that PIK3CD is a direct target of miR-30a
and miR-30b and may affect tumor cell survival-inhibiting cell migration and invasion [44,45]. Shi et al. showed that
miRNA-663 inhibited the proliferation and invasion of glioblastoma cells in vitro and in vivo by directly targeting
PIK3CD [46]. Various studies demonstrated that miR-125b acted as a tumor suppressor through suppression of the
PI3K/AKT signaling pathway by targeting the PIK3CD gene. These findings were observed in anaplastic thyroid
cancer, cervical cancer and Ewing’s sarcoma [47–49].
Recent findings have shown that ATM is a direct target of miR-203, miR-101 and miR-421 [50–52]. Studies
in colorectal cancer showed that miR-203 negatively regulates ATM by binding to a conserved site of the ATM
3′-UTR-inducing cell growth delay and senescence and investigations showed that miR-203 and ATM have an
important role in inducing an acquired chemoresistant phenotype in CRC cells [50]. Overexpression of miR-
101 inhibits the expression of DNA-PKcs and ATM in lung cancer and glioma cells and thus sensitizes tumors
to radiation [51]. Studies in neuroblastoma showed that miR-421 and ATM expression are inversely correlated
inducing tumorigenesis in neuroblastoma [52].
Investigations have shown that PTEN is a direct target of miR-153, miR-214, miR-93, miR-152, miR-221,
miR-130b and miR-103. These miRNAs act as oncomiRs promoting prostate cancer, breast cancer, hepatocellular
carcinoma, nasopharyngeal carcinoma, cervical cancer, esophageal squamous carcinoma and colorectal cancer
development, respectively [53–59]. Moreover, recent studies showed that miR-21 and miR-193a-3p targets PTEN in
a several types of cancers promoting uncontrolled growth, metabolism and metastasis [60].
Du et al. identified TSC1 as a direct target of miR-451. These findings were observed in myeloma cell lines and
in vivo. Thus, miR-451 mediate PI3K/AKT/mTOR pathway that plays an essential role in myeloma stem cell
biology [61]. Wan et al. showed that miR-155 could suppress the activation of mTORC1 and AKT through the
inhibition of Rheb and Rictor in nasopharyngeal carcinoma and cervical cancer cell lines. miR-155 attenuates cell
proliferation and induces G1/S cell cycle arrest [62]. Investigations in oral cancer, medulloblastoma and prostate
cancer demonstrated that miR-218 acts as a tumor suppressor by directly binding to Rictor-inhibiting tumori-
genesis [63–65]. Investigations have shown that TSC2 is a direct target of miR-221 in pancreatic cancer, thyroid
papillary carcinoma, breast cancer, glioblastoma, NSCLC, small-cell lung cancer and hepatic cellular cancer. On
the contrary, miR-451 targets TSC2 in glioma. These miRNAs promote tumor development [60].
Several studies showed that mTOR is a direct target of various miRNAs. Lin et al. demonstrated that miR-101 is
a tumor-suppressor gene, often found to be downregulated in osteosarcoma. Overexpression of miR-101 inhibits
osteosarcoma cell proliferation and promotes apoptosis by targeting mTOR [66]. Investigations showed that miR-
99a plays an important role in breast cancer by directly targeting mTOR and reversing the breast cancer malignant
phenotype [67]. Recent studies demonstrated that miR-7 and miR-496 inhibit mTOR. These findings were observed
in hepatocellular carcinoma and cervical cancer, respectively [43,68]. Investigations in bladder urothelial cancer and
chondrosarcoma showed mTOR as a direct target of miR-100. These miRNAs act as tumor suppressor by inhibiting
PI3K/AKT/mTOR signaling [69,70].
Several studies demonstrated that AKT1 is a direct target of miR-185, miR-99a and miR-542–3p and these
findings were observed in lung cancer and astrocytoma. These facts suggest that proliferation, migration and
invasion are regulated by these miRNAs [71–73].
Recent findings showed that miR-137, miR-302b and miR-184 regulate PI3K/AKT signaling through the direct
inhibition of AKT2 in gastric cancer, hepatocellular carcinoma and neuroblastoma studies, respectively [74–76].
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Table 1. miRNAs that are deregulated in renal cell carcinoma and target different components of
PI3/AKT/mTOR pathway.
Up-
/downregulation
miRNAs Function Target genes Tissues/cell
lines/serum/in vivo
Subtype Ref.
↗ miR-92 OncomiR VHL Tissues/cell lines ccRCC; papillary
RCC and
chromophobe RCC
[81]
↗ miR-21 OncomiR PTEN Tissues/cell lines – [79,80]
↙ miR-22 OncomiR PTEN Tissues/cell lines ccRCC [82]
↗ miR-23b-3p OncomiR PTEN Tissues/cell lines – [83]
↙ miR-99a Tumor suppressor mTOR Tissues/cell lines/nude
mice
– [84]
↙ miR-144 Tumor suppressor MTOR Tissues/cell lines – [85]
↙ miR-137 Tumor suppressor Predicted
target: PI3K/AKT
Tissues/cell lines/BALB/c
mice
– [86]
↙ miR-182–5p Tumor suppressor HIF-2 Tissues/cell lines/BALB/c
nude mice
ccRCC [87]
↙ miR-101 Tumor suppressor DNA-PKcs Tissues/cell
lines/nude/beige mice
– [88]
↙ miR-148a Tumor suppressor AKT2 Tissues/cell lines ccRCC [89]
AKT: Protein kinase B; ccRCC: Clear cell renal cell carcinoma; DNA-PKcs: DNA-dependent protein kinase; HIF: Hypoxia-inducible factor; PI3K: Phosphoinositide 3-
kinase; VHL: von Hippel–Lindau pathway.
Studies in hepatocellular carcinoma showed that AKT3 is a direct target of miR-144 and miR-122 [77,78].
Wu et al. demonstrated that miR-489 negatively regulate AKT3 expression by direct binding sites in its 3′-UTR.
Thus, these miRNAs inhibit cell growth [79].
miRNAs & PI3K/AKT/mTOR pathway in RCC
In this section, we will focus on the functional role of miRNAs in the regulation of PI3K/AKT/mTOR pathway
in RCC. A comprehensive list of miRNAs targeting this pathway is listed in Table 1.
miRNA-21 is involved in cellular mechanisms such as cell growth, apoptosis, cell cycle, invasion and migration
of tumor cells and this miRNA inhibits PTEN, a tumor suppressor gene. Therefore, significantly higher miR-21
levels were associated with higher stage and tumors grade and these results were demonstrated in RCC tissues and
cell lines [80,81]. Studies in samples of RCC tissues and cell lines showed that a higher expression of miR-92 may be
related to a more aggressive phenotype by inhibiting the VHL expression [82].
Fan et al. showed that miR-22 is downregulated in ccRCC and presents the ability to inhibit cell growth,
migration and invasion by directly targeting PTEN. These findings were demonstrated in tumor tissues and cell
lines [83]. Investigations in RCC tissues and cell lines demonstrated that miR-23b-3p is an oncogene and directly
inhibits the PTEN tumor-suppressor gene [84].
Recent findings have shown that miR-99a, miR-137, miR-182–5p and miR-101 were downregulated in RCC.
Cui et al. identified in patient’s tissues and cell lines the miR-99a as a potential tumor suppressor by inhibiting
mTOR and these results were also demonstrated in vivo [85]. Recent studies showed in patient tissue samples and
cell lines that miR-144 inhibits cell proliferation of RCC by directly targeting mTOR [86].
Zhang and Li showed in patient tissues, cell lines and in vivo xenograft models that miR-137 acts as a tumor
suppressor by inhibiting the PI3K/AKT pathway [87].
Downregulation of miR-182–5p plays an important role in the pathogenesis of RCC. Studies demonstrate that
this miRNA functions as a tumor suppressor, by inhibiting HIF-2α, a promoter of tumor growth and angiogenesis.
These results were consistent with the in vivo findings [88].
Zheng et al. showed that miR-101 level was significantly lower in human RCC tissues and cell lines and inhibits
indirectly the mTOR pathway by targeting DNA-PKcs, a member of PI3K, that regulates mTOR activation. Studies
in xenograft models in vivo showed that DNA-PKcs inhibition or silencing supresses AKT phosphorylation, HIF-
2α expression and tumor growth [89]. Recent investigations in RCC tissues and cell lines demonstrated that AKT2
is a direct target of miR-148a [90].
future science group 10.2217/pgs-2017-0160
Review Nogueira, Dias, Teixeira & Medeiros
In summary, miRNAs have been clearly demonstrated to have relationships with mTOR signaling pathway in
RCC. Expression profiling of miRNAs has been used to understand the development, invasion and progression
of cancer since they interfere with many different cellular processes and they can act as a tumor suppressor or
oncogenes to promote uncontrolled growth, metabolism and metastasis.
The involvement of miRNAs in the pathogenesis of RCC, describing their potential as novel diagnostic and
prognostic biomarkers, as well as predictive biomarkers for therapeutic response [91].
Because mTOR is a validated therapeutic target for cancer, and the clinical practice is facing some problems due
to the development of resistance to anti-mTOR therapies, targeting these miRNAs may provide a novel approach
to facilitate an integrated anticancer therapy [92].
Two therapeutic strategies may be applied using miRNAs: inhibition or replacement. Through the delivery of
antagomiRs, we are able to silence endogenous oncomiRs, therefore inhibiting their action on tumor-suppressor
mRNAs. On the other hand, through the ectopic replacement of tumor-suppressive miRNAs, by delivery primary
miRNA or miRNA synthetic mimics, we can restore tumor-suppressive miRNAs levels. Both these mechanisms
of miRNA delivery can be made in several ways, such as inside exosomes, which allow a targeted approach with
minimal side effects for the patients [93].
The efficacy and safety of miRNA-derived drugs must be carefully assessed and it will depend on the tumor
cells type and context [94]. Moreover, circulating miRNAs may be captured for liquid biopsy, since alterations in
their expression levels can be related to prognosis and therapy response prediction. The specificity and sensitivity
of mTOR inhibitors may be further improved by using these new therapeutic approaches [60].
Conclusion & future perspective
In this review, we highlighted an altered pathway in RCC that may be further studied to improve diagnosis and
prognosis as well as the development of new therapeutic strategies. PI3K/AKT/mTOR pathway is altered in the
majority of cancer cells-promoting tumorigenesis. This pathway is induced as a consequence of the one of the first
molecular events associated with RCC, and can be modulated by several miRNAs.
Since these miRNAs seem to be deregulated in cancer, one new therapeutic approach could be restoring suppressor
miRNAs levels or the inhibition of oncogenic miRNAs, which would inhibit mTOR signaling and, consequently,
one of the major deregulated pathways in tumorigenesis. Further studies are necessary to demonstrate and validate
the application of the previously described miRNAs as therapeutic candidates for RCC management.
In the future, the knowledge of the expression profile of mTOR-related miRNAs may contribute to the
monitorization of targeted therapies response in order to predict the resistance to mTOR therapies and, consequently,
improve the patients’ follow-up and care.
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Executive summary
Renal cell carcinoma
 Renal cell carcinoma (RCC) is the most common renal malignancy, and the most lethal urological cancer.
 RCC is a heterogeneous cancer which is divided into various subtypes. The most common subtype of RCC is clear
cell RCC (ccRCC), accounting for approximately 80% of all cases.
 One of the signaling pathways involved in the pathophysiology of ccRCC is the von Hippel–Lindau pathway. In
consequence of the alterations of von Hippel–Lindau pathway, the degradation of hypoxia-inducible factor stops,
which leads to its accumulation in the cytoplasm and further migration to the nucleus, where it binds to
hypoxia-related genes.
 Another ccRCC oncogenic mechanism involves the activation of the mTOR pathway. The mTOR signaling serves as
a central regulator of cell metabolism, growth, proliferation and survival.
 The discovery of these pathways in ccRCC pathogenesis allowed the development of targeted therapies:
angiogenesis inhibitors (multikinase inhibitors) and mTOR inhibitors.
Resistance to target therapies in RCC
 Drug resistance in ccRCC occurs to enable cancer cells survival and it is present in the currently used targeted
therapies, such as VEGF and mTOR inhibitors.
 These facts point to an urgent need to make further investigations of the molecular pathology of ccRCC and
identification of potential biomarkers that are predictive of tumor sensitivity to mTOR-targeted therapies.
miRNAs & cancer
 miRNAs are a family of small noncoding RNAs that regulate gene expression at the post-transcriptional level, by
binding to the complementary region of corresponding mRNAs leading to the inhibition or degradation of
mRNAs.
 miRNAs are expressed or inhibited in different types of cancer, suggesting that miRNAs work as oncomiRNAs or
tumor-suppressor miRNAs.
 These small molecules can be considered as potential diagnostic and prognostic biomarkers, as well as predictive
biomarkers for therapeutic response allowing disease monitorization.
 The circulating levels of specific miRNAs are promising noninvasive blood-based biomarkers.
miRNAs & PI3/AKT/mTOR pathway
 miRNAs have an important role in regulation of mTOR signaling in most cancer types, including RCC.
 miR-101 level was significantly lower in human RCC tissues and cell lines and inhibits indirectly the mTOR
pathway by targeting DNA-dependent protein kinase, and that regulates mTOR activation.
 Two therapeutic strategies may be applied using miRNAs in order to reverse mTOR therapy resistance: through
the delivery of antagomiRs in order to silence endogenous oncomiRs, and through ectopic replacement of
tumor-suppressive miRNAs by delivery primary miRNA or miRNA synthetic mimics.
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